Compare Global X Artificial Intelligence & Technology ETF (AIQ) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Global X Artificial Intelligence & Technology ETF vs Twist Bioscience Corp — how do they compare? Global X Artificial Intelligence & Technology ETF trades at $62.06, while Twist Bioscience Corp trades at $89.31 (market cap $5.67B). The key difference: Twist Bioscience Corp is trading nearer its 52-week high, Global X Artificial Intelligence & Technology ETF nearer its low. Which is the better fit depends on your goals.
| AIQ | TWST | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $70.14 | $102.88 |
52-Week Low | $43.28 | $24.16 |
Market Cap | — | $5.67B |
Enterprise Value | — | $5.59B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AIQ trades at $63.84, up 3.22% with a neutral technical signal. The ETF shows strong momentum with moving averages indicating bullish sentiment while oscillators remain neutral. Recent performance highlights include turning $10,000 into $13,400 over six months, outperforming broader market indices. The fund has gained attention for its AI-focused strategy amid expanding market interest beyond mega-cap technology stocks.
The outlook remains positive as AI adoption accelerates, though valuations require monitoring. Key risks include thematic ETF concentration and fee structure considerations. Institutional interest in AI infrastructure spending supports long-term growth potential, but market volatility around AI stock rotations presents near-term challenges.
Twist Bioscience (TWST) trades at $91.03, down 8.27% in the past day, amid mixed earnings performance. The stock shows a bullish technical trend with strong moving average signals, though RSI levels indicate overbought conditions. Revenue growth remains robust, rising to $377 million in 2025, but profitability challenges persist with a net income margin of -19.85%. Recent news highlights AI-driven drug discovery collaborations and insider selling activity.
The outlook is cautiously optimistic given analyst consensus favoring buys (76.93%) and a price target near current levels. Key risks include sustained cash burn, competitive pressures in synthetic biology, and execution on path to profitability. Upside hinges on revenue acceleration and margin improvement from new product launches and AI partnerships.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Global X Artificial Intelligence & Technology ETF
AIQ invests in companies that benefit from the development and utilization of artificial intelligence. It focuses on hardware, software, and data giants at the center of the AI revolution, including NVIDIA, Meta, and Broadcom.
Read more on AIQ →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
